ABVC Biopharma Collaboration Between ABVC And Oncox Biopharma, ABVC Expecting Aggregate Income Of $13.75M And Royalties Of Up To $12.50M; Grants Oncox Exclusive Rights For One Of Abvc's Four Products In Its Oncology Pipeline To Develop, Manufacture,...
ABVC Biopharma Collaboration Between ABVC And Oncox Biopharma, ABVC Expecting Aggregate Income Of $13.75M And Royalties Of Up To $12.50M; Grants Oncox Exclusive Rights For One Of Abvc's Four Products
Why Tesla Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Shares of Tesla, Inc. (NASDAQ:TSLA) rose sharply in today's pre-market trading following first-quarter results.Tesla posted weaker-than-expected earnings and sales results for its first quarter on Tue
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers180 Life Sciences (NASDAQ:ATNF) shares moved upwards by 7.4% to $2.04 during Tuesday's after-market session. The market value of their outstanding shares is at $1.7 million. ABVC BioPharma (NAS
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
FREMONT, CA, April 18, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology,
ABVC BioPharma Executes Licensing Agreement With OncoX
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersRallybio (NASDAQ:RLYB) shares rose 31.9% to $2.15 during Wednesday's after-market session. The company's market cap stands at $81.2 million. Vera Therapeutics (NASDAQ:VERA) shares increased by
ABVC Biopharma Stock Climbs on Deal for Its Oncology/hematology Products
Market-Moving News for April 10th
ADIL: 108% | Adial Pharmaceuticals shares are trading higher after the company announced the publication of a peer-reviewed article highlighting the clinical results, strong safety profile, and high c
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
FREMONT, CA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology,
12 Health Care Stocks Moving In Monday's After-Market Session
GainersOpGen (NASDAQ:OPGN) shares moved upwards by 24.0% to $0.74 during Monday's after-market session. The market value of their outstanding shares is at $7.4 million. Galecto (NASDAQ:GLTO) shares in
VERI, CHEK and MESO Are Among Pre Market Gainers
Why ABVC BioPharma Stock Is Up Today
ABVC BioPharma, Inc. (NASDAQ:ABVC) shares are trading higher Tuesday after the company announced it has entered into a global licensing agreement with ForSeeCon Eye Corporation for the company's ophthalmology pipeline.
NeuBase Therapeutics, ABVC BioPharma, Stoke Therapeutics Among Healthcare Movers
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersStoke Therapeutics (NASDAQ:STOK) stock increased by 80.2% to $11.71 during Tuesday's pre-market session. The market value of their outstanding shares is at $522.8 million. As per the press rele
ABVC BioPharma Entered Into a Global Licensing Deal of Vitargus With Licensing Income of $33.5M and Royalties up to $60M
FREMONT, CA, March 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology,
AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars
FREMONT, CA, March 21, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in
ABVC BioPharma, Inc. CEO Selected as 2024 Top 10 CEO in CEO Insights Asia Magazine
ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, proudly announced today that its CEO, Dr. Uttam Patil, was selected as one of the Top 10 CEOs in Taiwan 2024 by CEO Insights Asia Magazine.
ABVC BioPharma GAAP EPS of -$2.43, Revenue of $0.15M
ABVC BioPharma 2023 Rev $152,430 >ABVC
ABVC BioPharma 2023 Rev $152,430 >ABVC
No Data